CYCLIC COMPOUND

Publication EP3511320A1 Kind: A1 Mar 18, 2026

Applicants

Takeda Pharmaceutical Company Limited

Inventors

KOBAYASHI, Toshitake, SAITOH, Morihisa, WADA, Yasufumi, NEGORO, Nobuyuki, YAMASAKI, Masashi, TANAKA, Takahiro, KITAMOTO, Naomi

Abstract

The present invention provides a compound having a superior Toll-like receptor 4 (TLR4) signaling inhibitory action, which may be useful as a prophylactic or therapeutic drug for diseases such as autoimmune diseases and/or inflammatory diseases, or chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver failure, and ischemia reperfusion injury (IRI).The present invention relates to ethyl 6-((2-chloro-4-fluorobenzyl)sulfonyl)-3-hydroxycyclohex-1-ene-1-carboxylate or an optical isomer thereof.

IPC Classifications

C07C 317/46 20060101AFI20200306BHEP A61K 31/235 20060101ALI20200306BHEP A61P 1/16 20060101ALI20200306BHEP A61P 9/10 20060101ALI20200306BHEP A61P 25/02 20060101ALI20200306BHEP A61P 29/00 20060101ALI20200306BHEP A61P 37/02 20060101ALI20200306BHEP A61P 43/00 20060101ALI20200306BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →